Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was A$53.01 Mil.
EZZ Life Science Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.89 Mil. EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ASX:EZZ'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -356.95 Med: 33.23 Max: 26907.15
Current: 75.19
During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of EZZ Life Science Holdings was 26907.15%. The lowest was -356.95%. And the median was 33.23%.
ASX:EZZ's Earnings Yield (Joel Greenblatt) % is ranked better than 98.88% of 1337
companies
in the Biotechnology industry
Industry Median: -10.36
vs ASX:EZZ: 75.19
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. EZZ Life Science Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
EZZ Life Science Holdings Earnings Yield (Joel Greenblatt) % Related Terms
EZZ Life Science Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) % falls into.
EZZ Life Science Holdings Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
EZZ Life Science Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
EZZ Life Science Holdings (ASX:EZZ) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on EZZ Life Science Holdings and its competitors. According to the industry distribution chart, EZZ Life Science Holdings ranks #15 out of 1337 companies in the Biotechnology industry, placing it in the top 1.1%.
Is EZZ Life Science Holdings' Earnings Yield (Joel Greenblatt) % too high?
EZZ Life Science Holdings' current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, EZZ Life Science Holdings ranks #15 out of 1337 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #15 out of 1337 companies for Earnings Yield (Joel Greenblatt) %. This places EZZ Life Science Holdings in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on EZZ Life Science Holdings and its competitors. EZZ Life Science Holdings's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.49, compared to a current price of A$0.47 — trading 68.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.00%. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.47 is trading 68.5% below its estimated GF Value™ of A$1.49.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
Earnings Yield (Joel Greenblatt) %: 0.00%
GF Value™: A$1.49 vs. price of A$0.47 (68.5% below fair value)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score
Get the complete analysis for ASX:EZZ
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
